Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Cerilliant
Cipla
Merck
Fuji
Fish and Richardson
McKesson
Federal Trade Commission
Healthtrust

Generated: December 10, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR PHENTERMINE HYDROCHLORIDE

« Back to Dashboard

Clinical Trials for Phentermine Hydrochloride

Trial ID Title Status Sponsor Phase Summary
NCT00000506 Cardiovascular System in Obesity: Effect of Treatment Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 2 To determine the long-term efficacy of the combination therapy of phentermine and fenfluramine in conjunction with diet, exercise, and behavior modification in the treatment of simple, moderate obesity.
NCT00402077 A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects Completed AstraZeneca Phase 2 This study will examine the safety, tolerability, and body weight effect of subcutaneous pramlintide alone and in various combinations with the oral antiobesity agents sibutramine or phentermine in overweight and obese subjects.
NCT00518466 Pharmacokinetic Comparison of Multiple Formulations of Topiramate and Phentermine in Obese Adults Completed VIVUS, Inc. Phase 1 The primary objective of this study is to describe the single- and multiple-dose pharmacokinetic profiles of two novel formulations of topiramate and commercially available immediate release topiramate, all dosed with immediate release phentermine.
NCT00563368 A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults Completed Medpace, Inc. Phase 3 The objective of this study is to evaluate the safety and efficacy of various doses of VI-0521 compared to both placebo, and the single-agent components that comprise each combination dose. This study will provide confirmatory data to demonstrate that doses of VI-0521 have efficacy that is greater than placebo and each of the single-agent components that comprise the combination dose.
NCT00563368 A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults Completed VIVUS, Inc. Phase 3 The objective of this study is to evaluate the safety and efficacy of various doses of VI-0521 compared to both placebo, and the single-agent components that comprise each combination dose. This study will provide confirmatory data to demonstrate that doses of VI-0521 have efficacy that is greater than placebo and each of the single-agent components that comprise the combination dose.
NCT00600067 A VI-0521 Study to Evaluate the Long-term Safety and Efficacy in Type 2 Diabetic Adults Completed Sentrx Phase 2 The purpose of the study is to determine the long-term safety and efficacy of VI-0521 (phentermine/topiramate) compared to placebo in providing blood sugar control in Type 2 diabetic adults. Continuation of initial 6 month trial.
NCT00600067 A VI-0521 Study to Evaluate the Long-term Safety and Efficacy in Type 2 Diabetic Adults Completed Synteract, Inc. Phase 2 The purpose of the study is to determine the long-term safety and efficacy of VI-0521 (phentermine/topiramate) compared to placebo in providing blood sugar control in Type 2 diabetic adults. Continuation of initial 6 month trial.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Phentermine Hydrochloride

Condition Name

Condition Name for Phentermine Hydrochloride
Intervention Trials
Obesity 16
Drug Abuse 3
Diabetes 2
Healthy 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Phentermine Hydrochloride
Intervention Trials
Overweight 7
Obesity 4
Substance-Related Disorders 3
Feeding and Eating Disorders 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Phentermine Hydrochloride

Trials by Country

Trials by Country for Phentermine Hydrochloride
Location Trials
United States 67
Canada 1
Mexico 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Phentermine Hydrochloride
Location Trials
California 9
Texas 5
Florida 5
New York 4
Arizona 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Phentermine Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Phentermine Hydrochloride
Clinical Trial Phase Trials
Phase 4 5
Phase 3 2
Phase 2 8
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Phentermine Hydrochloride
Clinical Trial Phase Trials
Completed 16
Recruiting 5
Withdrawn 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Phentermine Hydrochloride

Sponsor Name

Sponsor Name for Phentermine Hydrochloride
Sponsor Trials
VIVUS, Inc. 7
AstraZeneca 4
Lindner Center of HOPE 2
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Phentermine Hydrochloride
Sponsor Trials
Industry 21
Other 19
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
US Department of Justice
Colorcon
Merck
Cantor Fitzgerald
Accenture
AstraZeneca
Citi
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.